Daclatasvir for the treatment of chronic hepatitis C virus infection.
Drugs Today (Barc)
; 51(5): 277-88, 2015 May.
Article
em En
| MEDLINE
| ID: mdl-26097901
ABSTRACT
Daclatasvir is a nonstructural protein 5A (NS5A) replication complex inhibitor that has shown potent in vitro activity against multiple hepatitis C virus (HCV) genotypes (GT). It is currently in advanced clinical development as a component of combination treatment regimens in a variety of HCV-infected patient populations. In studies conducted thus far, it has been generally well tolerated. It has been approved for the treatment of HCV GTs 1-4 in the European Union. The combination of daclatasvir and asunaprevir (an HCV NS3/4A protease inhibitor) has been approved in Japan for the treatment of patients with GT1 HCV infection. Here we review the available literature on daclatasvir, including its information on its discovery, mechanism of action, pharmacology, preclinical and clinical activity, resistance and safety.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Proteínas não Estruturais Virais
/
Hepatite C Crônica
/
Descoberta de Drogas
/
Imidazóis
Limite:
Humans
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article